IVIg and rituximab

DRUG2 trials

Sponsors

Cedars-Sinai Medical Center, Johns Hopkins University

Conditions

Kidney FailureKidney Transplant

Phase 1

Rituximab and Intravenous Immunoglobulin (IVIG) for Desensitization in Renal Transplantation

CompletedNCT00642655

Cedars-Sinai Medical CenterKidney Transplant

Start: 2005-09-30End: 2007-05-31Updated: 2008-03-25

Phase 2

Desensitization of Highly Sensitized Deceased Donor Renal Transplantation Candidates

TerminatedNCT00986947

Johns Hopkins UniversityKidney Failure

Start: 2009-09-30End: 2011-07-31Updated: 2017-06-01

Related Papers

Rituximab and intravenous immune globulin for desensitization during renal transplantation.

2008-07-01486 citations